Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 68 Show results per page	View Search Criteria \| Help With Results


1.		Vorinostat (MK0683, SAHA) Versus Placebo in Advanced Malignant Pleural Mesothelioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				2005_010 MK0683-014, NCT00128102


2.		Compassionate Use of Vorinostat (MK0683, SAHA) for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				2006_540 MK0683-042, NCT00419367


3.		Study of Vorinostat (MK0683) an HDAC Inhibitor, or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				2008_525 MK0683-088, NCT00773747

Last Modified: 2/18/2008 First Published: 5/5/2006


4.		Phase I/II Study of Vorinostat (SAHA) and Bevacizumab in Patients With Unresectable or Metastatic Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				JHOC-J0570 JHOC-00001107, NCI-6884, 6884, NCT00324870

Last Modified: 8/23/2006 First Published: 5/5/2006


5.		Phase I/II Study of Vorinostat (SAHA) in Combination With Isotretinoin in Patients With Advanced Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				21 and over				NCI				NYWCCC-0511008257 6896, NCI-6896, NCT00324740


6.		Vorinostat and IV Fluorouracil/Leucovorin (5FU/LV) in Patients With Metastatic Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				Over 18				Other				3C-05-3 NCT00336141

Last Modified: 4/24/2008 First Published: 10/21/2006


7.		Phase I/II Study of Vorinostat (SAHA) and Azacitidine in Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				NYCC-6898 6898, NCI-6898, NCT00392353


8.		Clinical Trial of SAHA in Patients With Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				BR03/20/05 DSRB Reference Code: B/06/275, HSA No: CTC0600314, NCT00416130


9.		Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				TARZO NCT00503971


10.		Vorinostat, Isotretinoin and Carboplatin in Adults With Recurrent Glioblastoma Multiforme (GBM)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				2006-0709 NCT00555399

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute